HOME >> MEDICINE >> NEWS
Faster and better emergency response through satellite telecoms

When emergency teams are well informed and governments can coordinate their efforts, lives and property can be saved. The Health Early Warning System, a project supported by ESA, is intended to bring this benefit to Europe.

Extreme natural phenomena like tsunamis, earthquakes and hurricanes have featured prominently in the news. So, too, has the rapid spread of new diseases such as SARS and avian flu. By identifying and mapping occurrences of these problems sooner, agencies can relieve suffering more quickly and contain a situation more efficiently. That is why ESA is supporting the Health Early Warning System (HEWS), which will improve the performance of emergency service end-users.

HEWS offers these users a wider, real-time perspective of events and how to manage them. It integrates knowledge of a particular threat or disease and brings it to remote areas, even if they are in an extreme state of disorder. It helps with logistical support and reduces the need to carry large amounts of heavy equipment to trouble spots.

A pan-European solution

HEWS works by setting up a communication network via satellite to survey and monitor risk indicators. It allows communication between teams in the field and with command centres. Data from many locations can be collected, stored and processed. It can then be quickly analysed and distributed to the users who need it the most. HEWS is an open platform, built using a modular approach, so the widest variety of users can implement it.

What will make HEWS critical to disaster relief agencies is that it is satellite based. Disasters may disrupt or even destroy local infrastructure but satellites are immune to their effects.

Two scenarios

The system will be tested in two different exercise scenarios, one African and one European. In the first, a suspected case of an infectious disease is reported. Field teams will be deployed by the local Minis
'"/>

Contact: Dominique Detain
dominique.detain@esa.int
33-015-369-7726
European Space Agency
9-May-2007


Page: 1 2

Related medicine news :

1. Faster, more accurate tuberculosis test developed
2. Faster, more efficient searching of medical images
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
5. Warfarin better than aspirin at stroke prevention in elderly people with atrial fibrillation
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Holograms make for better vision tests
9. Parents of chronically ill kids are helped by better access to federal and employer leave
10. Diabetes professionals join forces to identify gaps in diabetes care and better self care
11. Exploring better ways to determine when to change the course of treatment

Post Your Comments:
(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... OR (PRWEB) May 21, 2013 Phoseon ... systems at the 20th Annual IMI European Ink ... a proven market leader, Phoseon continues to invest in ... accelerating the adoption of UV LED curing in printing ... product families on the market offering both air cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
Cached News: